Glenmark Life Sciences

Company Description

• Biotechnology & Drugs

• BSE

  543322

• NSE

  GLS

• ISIN

  INE03Q201024

Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.